General discussion, page-295

@ringostar IP is everything, especially Novel IP.

For reference, BOTs run last year was mostly derived from the success of BTX 1801 trial for superbug killing.
Went from 10c to almost 30c, added an absolute ton of MC.
The study was done not even on an in-human trial but on an animal wound infection model.
It's the mere idea that if there is continued success of the novel IP, FDA approved that immense profits could follow.

Same concept applies to our 4 trials, outlined by Sud in his AGM talk and INCANNEX Preso.

We have 4 shots at the cake, and even initial success of just one of 4 will allow the oppies of Cannvalate and IHLOB to be exercised with ease, adding over 20M of funding, with more from Sud's own 20c oppies potentially in play.

This funding will allow for both working capital and funding for further trials, since the Cannvalate agreement only covers funding for the first initial 4.

The strategy is clear for IHL, and we have the cash balance to last another year at least. But, with IHLOB and Cannvalate oppies expiring this year it is critical that IHL can make sure they are all exercised. We all know what it would take to do this, successful trial results would lead to an enormous re-rate in the SP. Management surely knows this too, I bet that Sud probably drew up that options agreement himself.

We're slightly over halfway through this quarter, the critical quarter for OSA and the rest of the year is where the strategy for IHL is going to pay off or fail. We will find out soon, and those who don't think management can execute in the timelines that they likely came up with in the first place on time should sell now and save themselves the stress. For the rest of us, rest of the year will be exciting indeed.